Literature DB >> 33755929

Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease: A Difficult Equation.

Elias Sanidas1, Dimitrios Papadopoulos1, Michalis Chatzis1, Maria Velliou2, John Barbetseas1.   

Abstract

Chronic kidney disease (CKD) is a global health problem and is strongly associated with hypertension (HTN) and impaired quality of life. Managing HTN with agents that block the renin angiotensin aldosterone system (RAAS) remains the gold standard, however there is a misleading impression that patients with impaired renal function or those receiving hemodialysis should not be treated with RAAS inhibitors. To date, only a few data in this field are available, given that this population subset is systematically excluded from many major clinical trials. The purpose of this review was to solve the difficult equation regarding the optimal use of RAAS blockade in patients with CKD.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33755929     DOI： 10.1007/s40256-021-00467-9

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN： 1175-3277            Impact factor:   3.571


  39 in total

1.  2018 ESC/ESH Guidelines for the management of arterial hypertension.

Authors:  Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis L Clement; Antonio Coca; Giovanni de Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre E Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland E Schmieder; Evgeny Shlyakhto; Costas Tsioufis; Victor Aboyans; Ileana Desormais
Journal:  Eur Heart J       Date:  2018-09-01       Impact factor: 29.983

Review 2.  Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease.

Authors:  Helmy M Siragy; Robert M Carey
Journal:  Am J Nephrol       Date:  2010-05-18       Impact factor: 3.754

Review 3.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  Hypertension       Date:  2017-11-13       Impact factor: 10.190

4.  Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.

Authors:  P Ruggenenti; A Perna; G Gherardi; G Garini; C Zoccali; M Salvadori; F Scolari; F P Schena; G Remuzzi
Journal:  Lancet       Date:  1999-07-31       Impact factor: 79.321

Review 5.  Effects of RAAS Inhibitors in Patients with Kidney Disease.

Authors:  Fan Zhang; Hong Liu; Di Liu; Yexin Liu; Huiqiong Li; Xia Tan; Fuyou Liu; Youming Peng; Hongqing Zhang
Journal:  Curr Hypertens Rep       Date:  2017-08-08       Impact factor: 5.369

6.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

Authors:  E J Lewis; L G Hunsicker; R P Bain; R D Rohde
Journal:  N Engl J Med       Date:  1993-11-11       Impact factor: 91.245

7.  Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.

Authors:  G Maschio; D Alberti; G Janin; F Locatelli; J F Mann; M Motolese; C Ponticelli; E Ritz; P Zucchelli
Journal:  N Engl J Med       Date:  1996-04-11       Impact factor: 91.245

Review 8.  The global epidemiology of hypertension.

Authors:  Katherine T Mills; Andrei Stefanescu; Jiang He
Journal:  Nat Rev Nephrol       Date:  2020-02-05       Impact factor: 28.314

9.  Effects of Intensive BP Control in CKD.

Authors:  Alfred K Cheung; Mahboob Rahman; David M Reboussin; Timothy E Craven; Tom Greene; Paul L Kimmel; William C Cushman; Amret T Hawfield; Karen C Johnson; Cora E Lewis; Suzanne Oparil; Michael V Rocco; Kaycee M Sink; Paul K Whelton; Jackson T Wright; Jan Basile; Srinivasan Beddhu; Udayan Bhatt; Tara I Chang; Glenn M Chertow; Michel Chonchol; Barry I Freedman; William Haley; Joachim H Ix; Lois A Katz; Anthony A Killeen; Vasilios Papademetriou; Ana C Ricardo; Karen Servilla; Barry Wall; Dawn Wolfgram; Jerry Yee
Journal:  J Am Soc Nephrol       Date:  2017-06-22       Impact factor: 10.121

Review 10.  Management of Hypertension in Chronic Kidney Disease.

Authors:  Dan Pugh; Peter J Gallacher; Neeraj Dhaun
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546
View more
  1 in total

Review 1.  Chronic Kidney Disease and Cognitive Impairment: The Kidney-Brain Axis.

Authors:  Zuoquan Xie; Siyu Tong; Xingkun Chu; Teng Feng; Meiyu Geng
Journal:  Kidney Dis (Basel)       Date:  2022-05-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.